Juvenile Arthritis News

The FDA has approved Erelzi for all indications included in the reference product label, including rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and polyarticular juvenile idiopathic arthritis.

CLEVELAND — At the Rheumatology Nurses Society Annual Conference, <strong>John J. Cush, MD,</strong> director of clinical rheumatology at the Baylor Research Institute, spoke to <em>Healio/Rheumatology</em> about the management of patients with rheumatoid arthritis with methotrexate.

Results presented at the EULAR Annual Congress showed anti-tumor necrosis factor therapy improved both muscle and skin involvement in children with juvenile dermatomyositis.

According to results presented at the EULAR Annual Congress, subcutaneous abatacept was safe and effective for patients with polyarticular forms of juvenile idiopathic arthritis.

The FDA Arthritis Advisory Committee voted 20-0 in favor of recommending the approval of GP2015, Sandoz’s proposed biosimilar to Amgen’s Enbrel.

Results from this cross-sectional study showed parents used different styles of language, frames of reference and social media websites to express frustrations and issues with the heath care process both before and after their children were diagnosed with systemic juvenile idiopathic arthritis.

LONDON — Nearly 15% of adolescent patients diagnosed with juvenile idiopathic arthritis have significant depressive symptoms, and those with greater depressive symptoms have more inflamed joints and more disability, according to a speaker here at the EULAR Annual Congress.

Janssen Biologics B.V. announced the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending the use of subcutaneous golimumab in combination with methotrexate for the treatment of polyarticular juvenile idiopathic arthritis in children who had an inadequate response to methotrexate and weigh at least 40 kilograms.

Cancer was a relatively infrequent outcome among patients with juvenile-onset arthritis, according to study results.

Although results from this study indicated that having a first-degree relative with psoriasis should be disregarded as an exclusion criterion for psoriatic juvenile idiopathic arthritis, this information should still be used an inclusion criterion for the classification of the condition.